These companies are in the early days of their growth stories.If you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time ...

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year. There’s no better time for investors to look into the companies leading the charge and the stocks expected to perform best. These three biopharma stocks have products capitalizing on the surging demand for the latest, most popular drugs this year.We’ll detail the developments of ...

CRISPR Therapeutics AG (CRSP) closed at $71.96 in the latest trading session, marking a +0.69% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.57% for the day. At the same time, the Dow added 0.83%, and the tech-heavy Nasdaq gained 0.39%.Coming into today, shares of the company had lost 13.08% in the past month. In that same time, the Medical sector gained 0.13%, while the S&P 500 gained 2.97%.The upcoming earnings release of CRISPR Therapeutics AG will be of great inte ...

ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are thrilled to welcome Christian to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR T ...

CRISPR Therapeutics (CRSP -0.92%) was a standout in the market last month as its shares charged 34% higher, according to data provided by S&P Global Market Intelligence. The biotech stock sustained its momentum from prior months with a strong quarterly report and encouraging news from regulators.CRISPR keeps the good news rollingThere wasn't any transformative news out of CRISPR Therapeutics last month. Instead, the company sustained the excitement generated by important regulatory approvals over the past f ...

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day. This rapid increase in functionality means the technology might become a powerful assistant for market research. For us at InvestorPlace, this sparks curiosity as to just how good of a tool AI chatbots are for collecting investing advice.So we decided to look into OpenAI’s ChatGPT stock predictions on the best biotech stocks for t ...

Just one day after the ascendant biotech CRISPR Therapeutics (CRSP -1.62%) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the stock to $112, suggesting that it could rise by 32% from its current price. The company is in the process of commercializing its first medicine, a gene therapy called Casgevy that it developed to treat beta thalassemia and sickle cell disease (SCD) as part of a collaboration with Vertex Pharmaceuticals. Casgevy was ...

Key Points CRISPR Therapeutics made worldwide headlines coming into 2024, receiving the first-ever FDA approval for a gene editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Next-gen gene editing will evolve Cas9 from molecular scissors to a molecular UPS truck delivering cargo to a specific part of the genome. CTX-211 is in Phase 1 clinical trials for treating Type 1 diabetes (T1D) with the goal of enabling patients to produce their insulin instead of relying on ...

CRISPR Therapeutics (CRSP) reported earnings of $1.10 per share for the fourth quarter of 2023 against the Zacks Consensus Estimate of a loss of 40 cents. In the year-ago period, the company had incurred a loss of $1.41 per share.The positive result was driven by collaboration revenue received from Vertex (VRTX) in connection with the approval of Casgevy (exagamglogene autotemcel [exa-cel]) for two blood disorder indications. Shares of CRSP rose 4.7% on Feb 21 as investors cheered the encouraging financial ...

Ole_CNXCRISPR Therapeutics (NASDAQ:CRSP), a leader in the gene-editing revolution, has captivated the attention of scientists and investors alike and received much attention from investors like Cathy Wood. Over the past five years, the company has been on a rollercoaster ride with explosive growth, going from a promising scientific tool to a reality with tangible therapeutic applications. Dramatic breakthroughs, regulatory approvals, and, of course, volatile price movements have marked this journey. So, ...